A new germline point mutation in Ret exon 8 (Cys515Ser) in a family with medullary thyroid carcinoma

Thyroid

Volumn 18, Issue 7, 2008, Pages 775-782

  Fazioli, Francesca ^a,b   Piccinini, Gina ^a   Appolloni, Gloria ^a   Bacchiocchi, Roberta ^a   Palmonella, Gioia ^a   Recchioni, Rina ^a   Pierpaoli, Elisa ^a   Silvetti, Francesca ^a   Scarpelli, Marina ^a   Bruglia, Matteo ^a   Melillo, Rosa Marina ^c   Santoro, Massimo ^c   Boscaro, Marco ^a   Taccaliti, Augusto ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; DISULFIDE; HOMODIMER; LIGAND; PROTEIN RET; SERINE;

ADULT; ANIMAL CELL; ARTICLE; BIOCHEMISTRY; BIOLOGICAL ACTIVITY; CARCINOGENESIS; CASE REPORT; CELL GROWTH; CELL STRAIN 3T3; DIMERIZATION; EXON; FATHER; FEMALE; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROSCOPY; MITOGENESIS; MOUSE; NONHUMAN; NUCLEAR FAMILY; PAPILLARY CARCINOMA; POINT MUTATION; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA; UPREGULATION; WILD TYPE;

CARCINOMA, MEDULLARY; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; PEDIGREE; POINT MUTATION; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 47549103278     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2007.0365     Document Type: Article

References (31)

1. Ponder BA 1999 The phenotypes associated with Ret mutations in the multiple endocrine neoplasia type 2 syndrome. Cancer Res 59 (Suppl 7):1736-1741.
2. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiore PP 1995 Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267:381-383.
3. Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A 2004 RET: normal and abnormal functions. Endocrinology 145:5448-5451.
4. Arighi E, Borrello MG, Sariola H 2005 RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 16:441-467.
5. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman, SI, Lee JE, Evans DB 2005 Ret proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15:531-544.
6. Wigler M, Silverstein S, Lee LS, Pellicer A, Chen YC, Axel R 1977 Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell 11:223-232.
7. Carlomagno F, Vitagliano D, Guida T, Basolo F, Castellone MD, Melillo RM, Fusco A, Santoro M 2003 Efficient inhibition of Ret/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl) pyrazolo[3,4- d]-pyrimidine (PP2). J Clin Endocrinol Metab 88:1897-1902.
8. Tallini G, Santoro M, Helle M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu M, Fusco A 1998 RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 4:287-294.
9. Asai N, Murakami H, Iwashita T, Takahashi M 1996 A mutation at tyrosine 1062 in MEN 2A-Ret and Men 2B-Ret impairs their transforming activity in association with shc adaptor proteins. J Biol Chem 271:17644-17649.
10. Mercalli E, Ghizzoni S, Arighi E, Alberti L, Sangregorio R, Radice MT, Gishizky ML, Pierotti MA, Borrello MG 2001 Key role of shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein. Oncogene 20:3475-3485.
11. Ichihara M, Murakumo Y, Takahashi M 2004 Ret and neuroendocrine tumors. Cancer Lett 204:197-211.
12. Carlomagno F, Salvatore G, Cirafici AM, de Vita G, Melillo RM, de Franciscis V, Billaud M, Fusco A, Santoro M 1997 The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with multiple endocrine neoplasia type 2 disease phenotype. Cancer Res 57:391-395.
13. Ito S, Iwashita T, Asai N, Murakami H, Iwata Y, Sobue G, Takahashi M 1997 Biological properties of RET with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma and Hirschsprung's disease phenotype. Cancer Res 57:2870-2872.
14. Chappuis-Flament S, Pasini A, de Vita G, Ségouffin-Cariou C, Fusco A, Attié T, Lenoir GM, Santoro M, Billaud M 1998 Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines. Oncogene 17:2851-2861.
15. Cohen MS, Moley J 2003 Surgical treatment of medullary thyroid carcinoma. J Intern Med 253:616-626.
16. Giuffrida D, Gharib H 1998 Current diagnosis and management of medullary thyroid carcinoma. Ann Oncol 9:695-701.
17. Putzer BM, Drosten M 2004 The Ret proto-oncogene: a potential target for molecular cancer therapy. Trends Mol Med 10:351-357.
18. Pigny P, Bausters C, Wemeau JL, Houcke ML, Crepin M, Caron P, Giraud S, Calender A, Buisine MP, Kerchaert JP, Porchet N 1999 A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma. J Clin Endocrinol Metab 84:1700-1704.
19. Siggelkow H, Melzer A, Nolte W, Karsten K, Hoppner W, Hufner M 2001 Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the Ret proto-oncogene demonstrating low grade malignancy. Eur J Endocrinol 144:467-473.
20. Alvares Da Silva AM, Maciel RMB, Dias Da Silva MR, Toledo SRC, de Carvalho MB, Cerrutti JM 2003 A novel germ-line point mutation in RET exon 8 (Gly533Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab 88:5438-5443.
21. McIver B, Goellner JR, Hay ID 1996 Mixed medullary-papillary thyroid carcinoma in a patient with multiple endocrine neoplasia 2B (Men2B). Thyroid 6 (Suppl 1):16.
22. Rey JM, Brouillet JP, Fontenau-Allaire J, Boneu A, Bastié D, Maudelonde T, Pujol P 2001 Novel germline Ret mutation segregating with papillary thyroid carcinomas. Genes Chromosomes Cancer 32:390-391.
23. Orlandi F, Chiefari E, Caraci P, Mussa A, Gonzatto I, de Giuli P, Giuffrida D, Angeli A, Filetti S 2001 Ret proto-oncogene mutation in a mixed medullary-follicular thyroid carcinoma. J Endocrinol Invest 24:51-55.
24. Papi G, Corrado S, Pomponi MG, Carapezzi C, Cesinaro A, LiVolsi VA 2003 Concurrent lymph node metastases of medullary and papillary thyroid carcinoma in a case with ret oncogene germline mutation. Endocr Pathol 14:269-276.
25. Melillo RM, Cirafici AM, de Falco V, Ballantoni M, Chiappetta G, Fusco A, Carlomagno F, Picascia A, Tramontano D, Tallini G, Santoro M 2004 The oncogenic activity of Ret point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Am J Pathol 165:511-521.
26. Wiench M, Wygoda Z, Gubala E, Wloch J, Oczko M, Jarzab B 2001 The genetic background of medullary thyroid carcinoma in young patients. Folia Histochem Cytobiol 39 (Suppl 2):163-164.
27. Borrego S, Saez ME, Ruiz A, Gimm O, Lopez-Alonso M, Antinolo G, Eng C 1999 Specific polymorphisms in the Ret proto-oncogene are over-expressed in patients with Hirschsprung disease and may represent loci modifying phenotypic expression. J Med Genet 36:771-774.
28. Lesueur F, Corbex M, McKay JD, Lima J, Soares P, Griseri P, Burgess J, Ceccherini I, Landolfi S, Papotti M, Amorim A, Goldgar DE, Romeo G 2002 Specific haplotypes of the Ret proto-oncogene are over-expressed in patients with sporadic papillary thyroid carcinoma. J Med Genet 39:260-265.
29. Gimm O, Neuberg DS, Marsh DJ, Dahia PL, Hoang-Vu C, Raue F, Hinze R, Dralle H, Eng C 1999 Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. Oncogene 18:1369-1373.
30. Cebrian A, Lesueur F, Martin S, Leyland J, Ahmed S, Luccarini C, Smith PL, Luben R, Whittaker J, Pharoah PD, Dunning AM, Ponder BA 2005 Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6268-6274.
31. Gursoy A, Erdogan MF, Erdogan G 2006 Significance of the RET proto-oncogene polymorphisms in Turkish sporadic medullary thyroid carcinoma patients. J Endocrinol Invest 29:858-862.